A Phase 3 interventional study of vedolizumab and Placebo in Ulcerative Colitis, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 105 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-07-18.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 3rd largest by enrollment, is one of 2 that started in 2009, is one of 14 in phase 3, and was the 2nd registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Australia, Belgium and 15 more countries
Ages 2+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 895 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 110 across the 38 interventional studies. Of the 23 that completed or were terminated, 16 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
68 studies in Colitis, Ulcerative by Takeda: 6 open now, 10 under way, 5 of them phase 3. Of 54 finished, 35 (65%) have results posted.
Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 2nd largest by enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2009, is one of 21 in phase 3, and was the 8th registered.
Takeda’s Colitis, Ulcerative studies by the year they started, since 2003.
4 of the studies testing vedolizumab in Colitis, Ulcerative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 68 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
This multicenter, phase 3, randomized, blinded, placebo-controlled study in patients with moderately to severely active ulcerative colitis comprises two phases:
The 6-week Induction Phase contained 2 cohorts of participants: Cohort 1 participants were randomized and treated with double-blind study drug, and Cohort 2 participants were treated with open-label vedolizumab. The second cohort was enrolled to ensure that the sample size of Induction Phase responders randomized into the Maintenance Study provided sufficient power for the Maintenance Study primary efficacy analysis. These participants did not contribute to the efficacy analyses performed for the Induction Study. Participants in both cohorts were assessed for treatment response at Week 6.
In the Maintenance Phase vedolizumab-treated participants from both Cohort 1 and Cohort 2 who demonstrated a clinical response were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks (Q4W), vedolizumab administered every 8 weeks (Q8W), or placebo. Vedolizumab-treated participants who did not demonstrate response at Week 6 continued treatment with open-label vedolizumab, administered Q4W. Participants treated with double-blind placebo in the Induction Phase continued on double-blind placebo during the Maintenance Phase, regardless of treatment response during induction. The Maintenance Phase began at Week 6 and concluded with Week 52 assessments.
After the Week 52 assessments, participants meeting protocol-defined criteria were eligible to enroll in Study C13008 (NCT00790933; Long-term Safety) to receive open-label vedolizumab treatment. Participants who withdrew early (prior to Week 52) due to sustained nonresponse, disease worsening, or the need for rescue medications may also have been eligible for Study C13008. Participants who did not enroll into Study C13008 were to complete a final on-study safety assessment at Week 66 (or final safety visit 16 weeks after the last dose) in the Maintenance Phase of Study C13006.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each patient must meet all of the following inclusion criteria to be enrolled in the study:
Demonstrated, over the previous 5 year period, an inadequate response to, loss of response to, or intolerance at least 1 of the following agents:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15). In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase.
Drug: vedolizumab
In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
Other: Placebo
Vedolizumab for intravenous infusion
Also known as: Entyvio, MLN0002, MLN02, LDP-02
Placebo intravenous infusion
Induction Phase: Percentage of Participants With a Clinical Response at Week 6
Clinical response is defined as a reduction in complete Mayo score of ≥ 3 points and ≥ 30% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving clinical response.
Time frame: Baseline and Week 6
Maintenance Phase: Percentage of Participants in Clinical Remission at Week 52
Clinical Remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
Time frame: Week 52
Induction Phase: Percentage of Participants in Clinical Remission at Week 6
Clinical Remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
Time frame: Week 6
Induction Phase: Percentage of Participants With Mucosal Healing at Week 6
Mucosal healing is defined as a Mayo endoscopic subscore of ≤ 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern, mild friability); 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration). All participants who prematurely discontinued for any reason were considered as not achieving mucosal healing.
Time frame: Week 6
Maintenance Phase: Percentage of Participants With Durable Clinical Response
Durable clinical response is defined as reduction in complete Mayo score of ≥ 3 points and ≥ 30% from Baseline (Week 0) with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point at both Weeks 6 and 52. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving durable clinical response.
Time frame: Baseline, Week 6 and Week 52
Maintenance Phase: Percentage of Participants With Mucosal Healing at Week 52
Mucosal healing is defined as a Mayo endoscopic subscore of ≤ 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern, mild friability); 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration). All participants who prematurely discontinued for any reason were considered as not achieving mucosal healing.
Time frame: Week 52
Maintenance Phase: Percentage of Participants With Durable Clinical Remission
Durable clinical remission is defined as complete Mayo score of ≤ 2 points and no individual subscore \> 1 point at both Weeks 6 and 52. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving durable clinical remission.
Time frame: Week 6 and Week 52
Maintenance Phase: Percentage of Participants With Corticosteroid-free Remission at Week 52
Clinical Remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. Corticosteroid-free clinical remission is defined as participants using oral corticosteroids at baseline (Week 0) who discontinued corticosteroids and were in clinical remission at Week 52. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving corticosteroid-free remission.
Time frame: Week 52
Participants took part in the study at 211 investigative sites worldwide. The Induction Phase contained 2 cohorts. The eligibility criteria for both cohorts were identical. The purpose of Cohort 2 was to provide enough responders to power the Maintenance Phase primary efficacy analysis.
| Milestone | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab Q8W | Maintenance Phase: Vedolizumab Q4W | Maintenance Phase: Non-responders |
|---|---|---|---|---|---|---|---|
| Started | 149 | 225 | 521 | 0 | 0 | 0 | 0 |
| Completed | 135 | 218 | 485 | 0 | 0 | 0 | 0 |
| Not completed | 14 | 7 | 36 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 0 | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 5 | 2 | 14 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 4 | 8 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Maintenance Phase: Placebo | Maintenance Phase: Vedolizumab Q8W | Maintenance Phase: Vedolizumab Q4W | Maintenance Phase: Non-responders |
|---|---|---|---|---|---|---|---|
| Started | 135 | 0 | 0 | 126 | 122 | 125 | 330 |
| Completed | 30 | 0 | 0 | 48 | 77 | 84 | 135 |
| Not completed | 105 | 0 | 0 | 78 | 45 | 41 | 195 |
| Withdrew: Adverse event | 12 | 0 | 0 | 15 | 7 | 6 | 16 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Lack of efficacy | 83 | 0 | 0 | 61 | 31 | 33 | 155 |
| Withdrew: Withdrawal by subject | 6 | 0 | 0 | 2 | 5 | 2 | 20 |
| Withdrew: Lost to follow-up | 3 | 0 | 0 | 0 | 2 | 0 | 2 |
Clinical response is defined as a reduction in complete Mayo score of ≥ 3 points and ≥ 30% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving clinical response.
| percentage of participants | Placebo | DB Vedolizumab |
|---|---|---|
| Induction Phase: Percentage of Participants With a Clinical Response at Week 6 | 25.5 (18.5 to 32.5) | 47.1 (40.6 to 53.6) |
Clinical Remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
| percentage of participants | Placebo | Vedolizumab Q8W | Vedolizumab Q4W |
|---|---|---|---|
| Maintenance Phase: Percentage of Participants in Clinical Remission at Week 52 | 15.9 (9.5 to 22.3) | 41.8 (33.1 to 50.6) | 44.8 (36.1 to 53.5) |
Clinical Remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving clinical remission.
| percentage of participants | Placebo | DB Vedolizumab |
|---|---|---|
| Induction Phase: Percentage of Participants in Clinical Remission at Week 6 | 5.4 (1.7 to 9.0) | 16.9 (12.0 to 21.8) |
Mucosal healing is defined as a Mayo endoscopic subscore of ≤ 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern, mild friability); 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration). All participants who prematurely discontinued for any reason were considered as not achieving mucosal healing.
| percentage of participants | Placebo | DB Vedolizumab |
|---|---|---|
| Induction Phase: Percentage of Participants With Mucosal Healing at Week 6 | 24.8 (17.9 to 31.8) | 40.9 (34.5 to 47.3) |
Durable clinical response is defined as reduction in complete Mayo score of ≥ 3 points and ≥ 30% from Baseline (Week 0) with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point at both Weeks 6 and 52. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving durable clinical response.
| percentage of participants | Placebo | Vedolizumab Q8W | Vedolizumab Q4W |
|---|---|---|---|
| Maintenance Phase: Percentage of Participants With Durable Clinical Response | 23.8 (16.4 to 31.2) | 56.6 (47.8 to 65.4) | 52.0 (43.2 to 60.8) |
Mucosal healing is defined as a Mayo endoscopic subscore of ≤ 1 point. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern, mild friability); 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration). All participants who prematurely discontinued for any reason were considered as not achieving mucosal healing.
| percentage of participants | Placebo | Vedolizumab Q8W | Vedolizumab Q4W |
|---|---|---|---|
| Maintenance Phase: Percentage of Participants With Mucosal Healing at Week 52 | 19.8 (12.9 to 26.8) | 51.6 (42.8 to 60.5) | 56.0 (47.3 to 64.7) |
Durable clinical remission is defined as complete Mayo score of ≤ 2 points and no individual subscore \> 1 point at both Weeks 6 and 52. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving durable clinical remission.
| percentage of participants | Placebo | Vedolizumab Q8W | Vedolizumab Q4W |
|---|---|---|---|
| Maintenance Phase: Percentage of Participants With Durable Clinical Remission | 8.7 (3.8 to 13.7) | 20.5 (13.3 to 27.7) | 24.0 (16.5 to 31.5) |
Clinical Remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. Corticosteroid-free clinical remission is defined as participants using oral corticosteroids at baseline (Week 0) who discontinued corticosteroids and were in clinical remission at Week 52. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity). All participants who prematurely discontinued for any reason were considered as not achieving corticosteroid-free remission.
| percentage of participants | Placebo | Vedolizumab Q8W | Vedolizumab Q4W |
|---|---|---|---|
| Maintenance Phase: Percentage of Participants With Corticosteroid-free Remission at Week 52 | 13.9 (5.9 to 21.9) | 31.4 (20.6 to 42.3) | 45.2 (33.8 to 56.6) |
Collected over From the start of the Induction Phase until a final on-study safety assessment at Week 66 (or Final Safety visit 16 weeks after the last dose).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 17/149 (11.4%) | 67/149 (45%) |
| Vedolizumab Then Placebo | — | 20/126 (15.9%) | 69/126 (54.8%) |
| Vedolizumab | — | 77/620 (12.4%) | 321/620 (51.8%) |
| Event | Placebo | Vedolizumab Then Placebo | Vedolizumab |
|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 10/149 | 7/126 | 47/620 |
| AppendicitisInfections and infestations | 0/149 | 2/126 | 0/620 |
| Colon dysplasiaGastrointestinal disorders | 0/149 | 1/126 | 0/620 |
| Rectal haemorrhageGastrointestinal disorders | 0/149 | 1/126 | 0/620 |
| InfectionInfections and infestations | 0/149 | 1/126 | 0/620 |
| PneumoniaInfections and infestations | 0/149 | 1/126 | 0/620 |
| ConcussionInjury, poisoning and procedural complications | 0/149 | 1/126 | 0/620 |
| Pubis fractureInjury, poisoning and procedural complications | 0/149 | 1/126 | 0/620 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/149 | 1/126 | 0/620 |
| Aortic valve stenosisCardiac disorders | 0/149 | 1/126 | 0/620 |
| Event | Placebo | Vedolizumab Then Placebo | Vedolizumab |
|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 20/149 | 22/126 | 57/620 |
| NasopharyngitisInfections and infestations | 11/149 | 15/126 | 80/620 |
| HeadacheNervous system disorders | 13/149 | 15/126 | 80/620 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 10/149 | 15/126 | 56/620 |
| Upper respiratory tract infectionInfections and infestations | 8/149 | 13/126 | 52/620 |
| NauseaGastrointestinal disorders | 11/149 | 8/126 | 38/620 |
| AnaemiaBlood and lymphatic system disorders | 10/149 | 4/126 | 35/620 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/149 | 6/126 | 36/620 |
| BronchitisInfections and infestations | 5/149 | 7/126 | 23/620 |
| Abdominal painGastrointestinal disorders | 7/149 | 2/126 | 34/620 |
Baseline characteristics are provided for the Induction Phase Safety Population, defined as all participants, in both Cohort 1 and Cohort 2, who received any amount of study drug in the Induction Phase (Weeks 0-6), according to the actual study drug received.
| Age, Continuous(years) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| Mean | 41.2 ± 12.50 | 40.1 ± 13.11 | 40.1 ± 13.27 | 40.3 ± 13.09 |
| Age, Customized(participants) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| < 35 | 53 | 86 | 214 | 353 |
| ≥ 35 | 96 | 139 | 307 | 542 |
| Age, Customized(participants) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| < 65 | 142 | 217 | 503 | 862 |
| ≥ 65 | 7 | 8 | 18 | 33 |
| Sex: Female, Male(Participants) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| Female | 57 | 93 | 220 | 370 |
| Male | 92 | 132 | 301 | 525 |
| Race/Ethnicity, Customized(participants) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| White | 115 | 183 | 436 | 734 |
| Black | 2 | 5 | 5 | 12 |
| Asian | 32 | 36 | 67 | 135 |
| Other | 0 | 1 | 13 | 14 |
| Race/Ethnicity, Customized(participants) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 10 | 31 | 46 |
| Not Hispanic or Latino | 140 | 211 | 481 | 832 |
| Not reported | 4 | 4 | 9 | 17 |
| Region of Enrollment(participants) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| Australia | 7 | 17 | 29 | 53 |
| Austria | 4 | 3 | 12 | 19 |
| Belgium | 7 | 14 | 35 | 56 |
| Bulgaria | 2 | 1 | 3 | 6 |
| Canada | 16 | 14 | 62 | 92 |
| Czech Republic | 7 | 12 | 19 | 38 |
| Denmark | 2 | 7 | 5 | 14 |
| Estonia | 1 | 4 | 5 | 10 |
| France | 1 | 3 | 13 | 17 |
| Germany | 0 | 1 | 16 | 17 |
| Greece | 0 | 1 | 4 | 5 |
| Hong Kong | 0 | 0 | 1 | 1 |
| Hungary | 2 | 6 | 8 | 16 |
| Iceland | 0 | 1 | 2 | 3 |
| India | 18 | 16 | 24 | 58 |
| Ireland | 0 | 0 | 1 | 1 |
| Israel | 0 | 1 | 1 | 2 |
| Italy | 1 | 9 | 11 | 21 |
| Korea, Republic of | 5 | 10 | 26 | 41 |
| Latvia | 1 | 2 | 0 | 3 |
| Malaysia | 5 | 2 | 2 | 9 |
| Netherlands | 1 | 0 | 2 | 3 |
| New Zealand | 0 | 5 | 6 | 11 |
| Norway | 2 | 1 | 6 | 9 |
| Poland | 2 | 6 | 52 | 60 |
| Russian Federation | 9 | 15 | 25 | 49 |
| Singapore | 0 | 0 | 1 | 1 |
| South Africa | 4 | 5 | 10 | 19 |
| Spain | 0 | 0 | 2 | 2 |
| Switzerland | 2 | 1 | 3 | 6 |
| Turkey | 0 | 3 | 3 | 6 |
| United Kingdom | 2 | 0 | 4 | 6 |
| United States | 47 | 64 | 127 | 238 |
| Body Weight(kg) | Placebo | Induction Phase: DB Vedolizumab | Induction Phase: OL Vedolizumab | Total |
|---|---|---|---|---|
| Mean | 72.4 ± 17.65 | 72.4 ± 17.11 | 74.2 ± 19.32 | 73.4 ± 18.51 |
10 further baseline measures are reported on the registry.
Showing the first 100 of 105 sites across 3 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2009, a primary completion of Dec 2011 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 2 years 7 months after primary completion. A results delay was requested in Jan 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab
Millennium Pharmaceuticals, Inc. →